Incidence of anaemia among HIV - Infected patients treated with highly active antiretroviral therapy

HIV Medicine

Volumn 8, Issue 8, 2007, Pages 483-490

  Curkendall, S M ^a   Richardson, J T ^a   Emons, M F ^a   Fisher, A E ^b   Everhard, F ^b  

^a Cerner LifeSciences   (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

Anaemia; Highlyactive antiretroviral therapy; Incidence; Zidovudine

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ERYTHROPOIETIN; HEMOGLOBIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DISEASE SEVERITY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR;

ADULT; ANEMIA, HEMOLYTIC; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 35448983977     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00500.x     Document Type: Article

References (24)

1. Miles SA. Hematopoietic growth factors as adjuncts to antiretroviral therapy. AIDS Res Hum Retroviruses 1992; 8: 1073-1080.
2. Belperio PS, Rhew DC. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: A systematic review of the literature. Am J Med 2004; 116 (Suppl. 7A): 27S-43S.
3. Moore RD, Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29: 54-57.
4. Groopman JE. Zidovudine intolerance. Rev Infect Dis 1990; 12 (Suppl. 5): S500-S506.
5. Cohen H, Williams I, Matthey F, Miller RF, Machin SJ, Weller IV. Reversible zidovudine-induced pure red-cell aplasia. AIDS 1989; 3: 177-178.
6. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: Results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998; 91: 301-308.
7. Mocroft A, Kirk O, Barton SE et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA Study Group. AIDS 1999; 13: 943-950.
8. Lundgren JD, Mocroft A. Anemia and survival in human immunodeficiency virus. Clin Infect Dis 2003; 37 (Suppl. 4): S297-S303.
9. Berhane K, Karim R, Cohen MH et al. Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's interagency HIV study. J Acquir Immune Defic Syndr 2004; 37: 1245-1252.
10. Levine AM, Berhane K, Masri-Lavine L et al. Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's interagency HIV study. J Acquir Immune Defic Syndr 2001; 26: 28-35.
11. Moyle G, Sawyer W, Law M, Amin J, Hill A. Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: A meta-analysis of six prospective, randomized, comparative studies. Clin Ther 2004; 26: 92-97.
12. Ghani AC, Henley WE, Donnelly CA, Mayer S, Anderson RM. Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases. AIDS 2001; 15: 1133-1142.
13. Ghani AC, Donnelly CA, Anderson RM. Patterns of antiretroviral use in the United States of America: Analysis of three observational databases. HIV Med 2003; 4: 24-32.
14. Yuan Y, L'Italien G, Mukherjee J, Iloeje UH. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med 2006; 7: 156-162.
15. Iloeje UH, Yuan Y, L'Italien G et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005; 6: 37-44.
16. Tedaldi EM, Brooks JT, Weidle PJ et al. Increased body mass index does not alter response to initial highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr 2006; 43: 35-41.
17. Clark TG, Bradburn MJ, Love SB, Altman DG. Survival analysis part I: basic concepts and first analyses. Br J Cancer 2003; 89: 232-238.
18. Bradburn MJ, Clark TG, Love SB, Altman DG. Survival analysis part II: multivariate data analysis - an introduction to concepts and methods. Br J Cancer 2003; 89: 431-436.
19. Levy AR, Tamblyn RM, Abrahamowicz M, McLeod PJ, Fitchett D. Use of time-dependent measures to estimate benefits of beta-blockers after myocardial infarction. Pharmacoepidemiol Drug Saf 2004; 13: 623-631.
20. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
21. Wills TS, Nadler JP, Somboonwit C et al. Anemia prevalence and associated risk factors in a single-center ambulatory HIV clinical cohort. AIDS Read 2004; 14: 305.
22. Semba RD, Shah N, Klein RS, Mayer KH, Schuman P, Vlahov D. Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis 2002; 34: 260-266.
23. Semba RD, Shah N, Vlahov D. Risk factors and cumulative incidence of anaemia among HIV-infected injection drug users. Int J STD AIDS 2002; 13: 119-123.
24. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-920.